142 related articles for article (PubMed ID: 31463577)
1. Evaluation of potential surrogate endpoints for prediction of overall survival in patients with castration-resistant prostate cancer: trial-level meta-analysis.
Chen W; Li L; Ji S; Song X; Lu W; Zhou T
Eur J Clin Pharmacol; 2019 Nov; 75(11):1521-1532. PubMed ID: 31463577
[TBL] [Abstract][Full Text] [Related]
2. Searching for potential surrogate endpoints of overall survival in clinical trials for patients with prostate cancer.
Maeda H; Takeda K; Urushihara H; Kurokawa T
Cancer Rep (Hoboken); 2021 Jun; 4(3):e1334. PubMed ID: 33455091
[TBL] [Abstract][Full Text] [Related]
3. Correlation Between Imaging-Based Intermediate Endpoints and Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: Analysis of 28 Randomized Trials Using the Prostate Cancer Clinical Trials Working Group (PCWG2) Criteria in 16,511 Patients.
Woo S; Suh CH; Wibmer AG; Becker AS; Teo MY; Gönen M; Hricak H; Scher HI; Morris MJ; Vargas HA
Clin Genitourin Cancer; 2022 Feb; 20(1):69-79. PubMed ID: 34903480
[TBL] [Abstract][Full Text] [Related]
4. Longitudinal model-based meta-analysis for survival probabilities in patients with castration-resistant prostate cancer.
Chen W; Li L; Ji S; Song X; Lu W; Zhou T
Eur J Clin Pharmacol; 2020 Apr; 76(4):589-601. PubMed ID: 31925454
[TBL] [Abstract][Full Text] [Related]
5. Radiographic Progression-Free Survival as a Clinically Meaningful End Point in Metastatic Castration-Resistant Prostate Cancer: The PREVAIL Randomized Clinical Trial.
Rathkopf DE; Beer TM; Loriot Y; Higano CS; Armstrong AJ; Sternberg CN; de Bono JS; Tombal B; Parli T; Bhattacharya S; Phung D; Krivoshik A; Scher HI; Morris MJ
JAMA Oncol; 2018 May; 4(5):694-701. PubMed ID: 29522174
[TBL] [Abstract][Full Text] [Related]
6. Trial Level Analysis of Prostate-Specific Antigen-Related Versus Unrelated Endpoints in Phase III Trials of First-Line and Second-Line Medical Treatments of Patients With Metastatic Castration-Resistant Prostate Cancer.
Colloca G; Vitucci P; Venturino A
Clin Genitourin Cancer; 2016 Oct; 14(5):389-397. PubMed ID: 27108003
[TBL] [Abstract][Full Text] [Related]
7. Overall Survival in Men With Bone Metastases From Castration-Resistant Prostate Cancer Treated With Bone-Targeting Radioisotopes: A Meta-analysis of Individual Patient Data From Randomized Clinical Trials.
Terrisse S; Karamouza E; Parker CC; Sartor AO; James ND; Pirrie S; Collette L; Tombal BF; Chahoud J; Smeland S; Erikstein B; Pignon JP; Fizazi K; Le Teuff G;
JAMA Oncol; 2020 Feb; 6(2):206-216. PubMed ID: 31830233
[TBL] [Abstract][Full Text] [Related]
8. Meta-analyses evaluating surrogate endpoints for overall survival in cancer randomized trials: A critical review.
Savina M; Gourgou S; Italiano A; Dinart D; Rondeau V; Penel N; Mathoulin-Pelissier S; Bellera C
Crit Rev Oncol Hematol; 2018 Mar; 123():21-41. PubMed ID: 29482777
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Value of Androgen Receptor Splice Variant 7 in the Treatment of Castration-resistant Prostate Cancer with Next generation Androgen Receptor Signal Inhibition: A Systematic Review and Meta-analysis.
Li H; Wang Z; Tang K; Zhou H; Liu H; Yan L; Guan W; Chen K; Xu H; Ye Z
Eur Urol Focus; 2018 Jul; 4(4):529-539. PubMed ID: 28753843
[TBL] [Abstract][Full Text] [Related]
10. Sequencing of Taxanes and New Androgen-targeted Therapies in Metastatic Castration-resistant Prostate Cancer: Results of the International Multicentre Retrospective CATS Database.
Delanoy N; Hardy-Bessard AC; Efstathiou E; Le Moulec S; Basso U; Birtle A; Thomson A; Krainer M; Guillot A; De Giorgi U; Hasbini A; Daugaard G; Bahl A; Chowdhury S; Caffo O; Beuzeboc P; Spaeth D; Eymard JC; Fléchon A; Alexandre J; Helissey C; Butt M; Priou F; Lechevallier É; Deville JL; Goupil MG; Morales R; Thiery-Vuillemin A; Gavrikova T; Barthelemy P; Sella A; Fizazi K; Baciarello G; Fererro JM; Laguerre B; Verret B; Hans S; Oudard S
Eur Urol Oncol; 2018 Dec; 1(6):467-475. PubMed ID: 31158090
[TBL] [Abstract][Full Text] [Related]
11. Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer.
Sonpavde G; Pond GR; Armstrong AJ; Galsky MD; Leopold L; Wood BA; Wang SL; Paolini J; Chen I; Chow-Maneval E; Mooney DJ; Lechuga M; Smith MR; Michaelson MD
BJU Int; 2014 Dec; 114(6b):E25-E31. PubMed ID: 24298897
[TBL] [Abstract][Full Text] [Related]
12. Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches.
Damodaran S; Lang JM; Jarrard DF
J Urol; 2019 May; 201(5):876-885. PubMed ID: 30747897
[TBL] [Abstract][Full Text] [Related]
13. The value of surrogate endpoints for predicting real-world survival across five cancer types.
Shafrin J; Brookmeyer R; Peneva D; Park J; Zhang J; Figlin RA; Lakdawalla DN
Curr Med Res Opin; 2016; 32(4):731-9. PubMed ID: 26743800
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy with or without estramustine for treatment of castration-resistant prostate cancer: A systematic review and meta-analysis.
Qin Z; Li X; Zhang J; Tang J; Han P; Xu Z; Yu Y; Yang C; Wang C; Xu T; Xu Z; Zou Q
Medicine (Baltimore); 2016 Sep; 95(39):e4801. PubMed ID: 27684806
[TBL] [Abstract][Full Text] [Related]
15. Systematic Review and Network Meta-Analysis of Treatments for Chemotherapy-Naive Patients with Asymptomatic/Mildly Symptomatic Metastatic Castration-Resistant Prostate Cancer.
McCool R; Fleetwood K; Glanville J; Arber M; Goodall H; Naidoo S
Value Health; 2018 Oct; 21(10):1259-1268. PubMed ID: 30314628
[TBL] [Abstract][Full Text] [Related]
16. Comparative efficacy, tolerability, and survival outcomes of various radiopharmaceuticals in castration-resistant prostate cancer with bone metastasis: a meta-analysis of randomized controlled trials.
Tunio M; Al Asiri M; Al Hadab A; Bayoumi Y
Drug Des Devel Ther; 2015; 9():5291-9. PubMed ID: 26451085
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of testosterone for the castration-resistant prostate cancer patients: a systematic review and meta-analysis.
Miura N; Mori K; Mostafaei H; Quhal F; Sari Motlagh R; Abufaraj M; Pradere B; Aydh A; Laukhtina E; D'Andrea D; Saika T; Shariat SF
Int J Clin Oncol; 2020 Nov; 25(11):1881-1891. PubMed ID: 32681382
[TBL] [Abstract][Full Text] [Related]
18. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.
Clarke N; Wiechno P; Alekseev B; Sala N; Jones R; Kocak I; Chiuri VE; Jassem J; Fléchon A; Redfern C; Goessl C; Burgents J; Kozarski R; Hodgson D; Learoyd M; Saad F
Lancet Oncol; 2018 Jul; 19(7):975-986. PubMed ID: 29880291
[TBL] [Abstract][Full Text] [Related]
19. Alkaline phosphatase velocity predicts overall survival and bone metastasis in patients with castration-resistant prostate cancer.
Hammerich KH; Donahue TF; Rosner IL; Cullen J; Kuo HC; Hurwitz L; Chen Y; Bernstein M; Coleman J; Danila DC; Metwalli AR
Urol Oncol; 2017 Jul; 35(7):460.e21-460.e28. PubMed ID: 28410987
[TBL] [Abstract][Full Text] [Related]
20. Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial.
Saad F; Fizazi K; Jinga V; Efstathiou E; Fong PC; Hart LL; Jones R; McDermott R; Wirth M; Suzuki K; MacLean DB; Wang L; Akaza H; Nelson J; Scher HI; Dreicer R; Webb IJ; de Wit R;
Lancet Oncol; 2015 Mar; 16(3):338-48. PubMed ID: 25701170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]